The bleeding edge

The surging credit derivatives industry has experienced significant growing pains this year. While regulators are forcing dealers to tackle the issue of mounting unconfirmed trades, there are a number of technical and market-related barriers. By Hann Ho

Since the UK's Financial Services Authority (FSA) first aired its concern about the swelling volume of unconfirmed credit derivatives trades in February, dealers have scrambled to search for solutions to the problem. But it was not an issue they could solve easily. The regulatory spotlight then intensified, and culminated in a well-publicised September 15 meeting convened by the Federal Reserve Bank of New York, whose president, Timothy Geithner, told the 14 Wall Street dealers summoned that the

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Chartis RiskTech100® 2024

The latest iteration of the Chartis RiskTech100®, a comprehensive independent study of the world’s major players in risk and compliance technology, is acknowledged as the go-to for clear, accurate analysis of the risk technology marketplace. With its…

T+1: complacency before the storm?

This paper, created by WatersTechnology in association with Gresham Technologies, outlines what the move to T+1 (next-day settlement) of broker/dealer-executed trades in the US and Canadian markets means for buy-side and sell-side firms

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here